AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
vadadustat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors | 5420 | 1000025-07-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor induces endogenous erythropoietin synthesis and enhances iron mobilization.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.044 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 71.121 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 12.794 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.173 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.490 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.420 | % | High | 1 |
| herg | hERG pIC50 | 4.416 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.904 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.055 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.290 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,IKBKB,ITK,JAK1,KDR,KIT,MAP2K6,MAP3K21,MAPK7,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1 | 42 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,EIF2AK3,GRK2,PRKDC,TGFBR1 | 7 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 8.913 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 6.039 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 1.730 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.624 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.800 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 6.166 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 69.170 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.420 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 897.429 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 29, 2020 | PMDA | Mitsubishi Tanabe Pharma | |
| April 24, 2023 | EMA | AKEBIA EUROPE LIMITED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Marasmus | 79.97 | 60.30 | 9 | 46 | 814 | 90627578 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Marasmus | 95.72 | 60.63 | 13 | 192 | 1678 | 110587416 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B03XA08 | BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS Other antianemic preparations |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D064800 | Prolyl-Hydroxylase Inhibitors |
| FDA MoA | N0000190111 | Organic Anion Transporter 3 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000194079 | Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors |
| FDA EPC | N0000194080 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
B03XA Other antianemic preparations 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia of renal disease | indication | 234348004 | |
| Anemia in chronic kidney disease | indication | 707323002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8940773 | June 26, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8940773 | June 26, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8940773 | June 26, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8323671 | April 3, 2028 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8323671 | April 3, 2028 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 8323671 | April 3, 2028 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 12569474 | June 4, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 12569474 | June 4, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 12569474 | June 4, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11857543 | June 9, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11857543 | June 9, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11857543 | June 9, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11065237 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 9987262 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11065237 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 9987262 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11065237 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 9987262 | Nov. 14, 2034 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11844756 | March 31, 2036 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11844756 | March 31, 2036 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | 11844756 | March 31, 2036 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 150MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | March 27, 2029 | NEW CHEMICAL ENTITY |
| 300MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | March 27, 2029 | NEW CHEMICAL ENTITY |
| 450MG | VAFSEO | AKEBIA | N215192 | March 27, 2024 | RX | TABLET | ORAL | March 27, 2029 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Egl nine homolog 1 | Enzyme | INHIBITOR | IC50 | 7.81 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Egl nine homolog 2 | Enzyme | INHIBITOR | IC50 | 7.93 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Egl nine homolog 3 | Enzyme | INHIBITOR | IC50 | 8.12 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Vascular endothelial growth factor A | Secreted | EC50 | 5.12 | CHEMBL | |||||
| Hypoxia-inducible factor 1-alpha inhibitor | Enzyme | IC50 | 4.54 | CHEMBL | |||||
| Aspartyl/asparaginyl beta-hydroxylase | Enzyme | IC50 | 5.36 | CHEMBL | |||||
| Methylcytosine dioxygenase TET2 | Enzyme | IC50 | 5.30 | CHEMBL | |||||
| Prolyl 3-hydroxylase OGFOD1 | Enzyme | IC50 | 5.85 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 1 | Kinase | EC50 | 5.12 | CHEMBL | |||||
| Gamma-butyrobetaine dioxygenase | Enzyme | IC50 | 6.55 | CHEMBL | |||||
| Prolyl 4-hydroxylase | Enzyme | Ki | 6.55 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D11078 | KEGG_DRUG |
| I60W9520VV | UNII |
| C4519730 | UMLSCUI |
| CHEBI:755674 | CHEBI |
| A1Z | PDB_CHEM_ID |
| CHEMBL3646221 | ChEMBL_ID |
| 23634441 | PUBCHEM_CID |
| DB12255 | DRUGBANK_ID |
| 10289 | INN_ID |
| C000624313 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11831 | IUPHAR_LIGAND_ID |
| 1701801000168108 | SNOMEDCT_US |
| 4043278 | VANDF |
| 374936 | MMSL |
| 42224 | MMSL |
| d10143 | MMSL |
| 019623 | NDDF |
| 2679296 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VAFSEO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59922-641 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 32 sections |
| VAFSEO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59922-642 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 32 sections |
| VAFSEO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59922-643 | TABLET, FILM COATED | 450 mg | ORAL | NDA | 32 sections |